Orforglipron EU approval moved a step closer on 15 October 2026, when the European Medicines Agency’s human medicines committee recommended a marketing authorisation for Foundayo. The product is an oral, once-daily GLP-1 receptor agonist from Eli Lilly, and it would give European patients a weight-loss and diabetes treatment that comes as a tablet rather than an injection.
The committee backed Foundayo for two uses. In weight management, it covers adults with a body mass index of 30 or higher, or between 27 and 30 when a weight-related condition is also present. In type 2 diabetes, it covers adults whose disease is not adequately controlled, either as monotherapy when metformin is unsuitable or alongside other diabetes medicines. Patients take the film-coated tablet on prescription, with or without meals, and treatment starts at the lowest dose before rising gradually through six strengths from 0.8 mg to 17.2 mg.
The evidence behind the orforglipron EU approval recommendation comes from large trials. Two weight studies involving 4,740 adults showed weight loss of 5% to 11% after 72 weeks, depending on the dose, compared with 2% to 2.5% on placebo. Four diabetes studies involving 3,765 adults showed reductions in HbA1c of about 1.2 to 1.9 percentage points. Those results behind the orforglipron EU approval opinion show a clear benefit over placebo, and the convenience of a daily tablet could widen the pool of people willing to start treatment.
The opinion is only a recommendation. The European Commission takes the legally binding decision, and it usually does so within about 67 days of a committee opinion, which points to a decision around the end of 2026. A positive decision would give Foundayo a single authorisation valid in all 27 member states.
Authorisation does not mean access, and this is where the orforglipron EU approval story becomes a Brussels issue. Each member state sets pricing and reimbursement for itself, so patients in different countries may wait very different lengths of time, and some health systems may decline to fund obesity treatment broadly. National budgets already face pressure from ageing populations, and a pill that millions of adults could use would test the willingness of finance ministries to pay for prevention.
Health policymakers will also watch the supply side of orforglipron. A daily tablet is simpler to store and distribute than an injectable pen, so supply and availability will matter as much as price once an authorisation arrives. Foundayo therefore gives the EU debate on access to medicines a concrete case.
For now, the committee’s opinion on orforglipron marks the scientific step. The decisive stages still lie ahead, and the orforglipron EU approval will matter most when governments decide who gets the pill and who pays for it.
